TITLE

Inhaled corticosteroids and decline of lung function in community residents with asthma

AUTHOR(S)
Lange, P.; Scharling, H.; Ulrik, C. S.; Vestbo, J.
PUB. DATE
February 2006
SOURCE
Thorax;Feb2006, Vol. 61 Issue 2, p100
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Background: Inhaled corticosteroids (ICS) constitute the cornerstone of treatment for asthma. Many studies have reported beneficial short term effects of these drugs, but there are few data on the long term effects of ICS on the decline in forced expiratory volume in 1 second (FEV1). This study was undertaken to determine whether adults with asthma treated with ICS have a less pronounced decline in FEV1 than those not treated with ICS. Methods: Two hundred and thirty four asthmatic individuals from a longitudinal epidemiological study of the general population of Copenhagen, Denmark were divided into two groups; 44 were treated with ICS and 190 were not treated with ICS. The annual decline in FEV1 was measured over a 10 year follow up period. Results: The decline in FEV1 in the 44 patients receiving ICS was 25 mI/year compared with 51 mI/year in the 190 patients not receiving this treatment (p<0.001). The linear regression model with ICS as the variable of interest and sex, smoking, and wheezing as covariates showed that treatment with ICS was associated with a less steep decline in FEV1 of 18 mI/year (p=0.01). Adjustment for additional variables including age, socioeconomic status, body mass index, mucus hypersecretion, and use of other asthma medications did not change these results. Conclusions: Treatment with ICS is associated with a significantly reduced decline in ventilatory function.
ACCESSION #
19787740

 

Related Articles

  • Lung function decline in asthma: association with inhaled corticosteroids, smoking and sex. Dijkstra, A.; Vonk, J. M.; Jongepier, H.; Koppelman, G. H.; Schouten, J. P.; Ten Hacken, N. H. T.; Timens, W.; Postma, D. S. // Thorax;Feb2006, Vol. 61 Issue 2, p105 

    Background: Inhaled corticosteroids (ICS) provide short term benefits in asthma but the long term effects are still unknown. Methods: 281 patients diagnosed with moderate to severe asthma in 1963-75 were re-examined in 1991-9. Information was collected on forced expiratory volume in 1 second...

  • Treatment Comparison of Budesonide/ Formoterol with Salmeterol/Fluticasone Propionate in Adults Aged ≥16 Years with Asthma: Post Hoc Analysis of a Randomized, Double-Blind Study. Kuna, Piotr // Clinical Drug Investigation;2010, Vol. 30 Issue 9, p565 

    Background: Three fixed maintenance-dose inhaled corticosteroid/long-acting β2-agonist (ICS/LABA) combinations for the treatment of asthma are currently available: salmeterol/fluticasone propionate (Seretide™/Advair™/ Adoair™) budesonide/formoterol (Symbicort®) and...

  • LUNG CLEARANCE INDEX IN CHILDREN WITH ACUTE EXACERBATION OF ASTHMA. Sheridan, H. S.; Cunningham, S. // Thorax;Dec2011 Supplement, pA99 

    Introduction Lung clearance index (LCI) can detect small airways disease in asthma; however there is no published LCI data collected during acute exacerbation. We aimed to investigate LCI in asthmatic children requiring oral corticosteroids and admission to hospital. Methods Children were...

  • Are asthma-like symptoms in elite athletes associated with classical features of asthma? T K Lund // British Journal of Sports Medicine;Dec2009, Vol. 43 Issue 14, p1131 

    BACKGROUND: Asthma is frequent in elite athletes and clinical studies in athletes have found increased airway inflammation. OBJECTIVE: To investigate asthma-like symptoms, airway inflammation, airway reactivity (AR) to mannitol and use of asthma medication in Danish elite athletes. METHODS: The...

  • Inhaled corticosteroids moderate lung function decline in adults with asthma. Ernst, P. // Thorax;Feb2006, Vol. 61 Issue 2, p93 

    The paper describes a reduction in the decline in forced expiratory volume in 1 second (FEV1) over 10 years in patients with asthma aged over 30 years who were using inhaled corticosteroids throughout the observation period. Lange and colleagues conducted the study using information from the...

  • Omalizumab for Asthma: Indications, Off-Label Uses and Future Directions. Ben-Shoshan, Moshe // Recent Patents on Inflammation & Allergy Drug Discovery;Nov2010, Vol. 4 Issue 3, p183 

    Omalizumab is a recombinant humanized monoclonal antibody. Use of omalizumab is reported to benefit significantly a subset of asthmatics patients with inadequately controlled moderate-to-severe persistent allergic asthma that is not controlled with high-dose inhaled corticosteroids. However,...

  • Editorial [Guest Editor: Strategies for the Improvement of Asthma Therapy (Executive Editor: Andreas Pahl)]. Pahl, Andreas // Current Pharmaceutical Design;Sep2006, Vol. 12 Issue 25, p3173 

    Asthma bronchiale, affecting 155 millions people worldwide, has emerged as a major public health problem worldwide over the past 20 years. Although data indicate that current asthma therapies led to limited decreases in death rates, it continues to be a significant health care problem. As we...

  • Asthma: Principles of Treatment. Story, Rachel E.; Tripathi, Anju // Allergy & Asthma Proceedings;Jul/Aug2004, Vol. 25, pS26 

    The article presents information on the principles of treatment of Asthma. Proper treatment of asthma requires an accurate diagnosis of the type of asthma (allergic versus non allergic) as well as its severity. Once a diagnosis is established, coexisting conditions that affect asthma severity...

  • Fluticasone furoate demonstrates efficacy in patients with asthma symptomatic on medium doses of inhaled corticosteroid therapy: an 8-week, randomised, placebo-controlled trial. Busse, William W.; Bleecker, Eugene R.; Bateman, Eric D.; Lötvall, Jan; Forth, Richard; Davis, Angela M.; Jacques, Loretta; Haumann, Brett; Woodcock, Ashley // Thorax;Jan2012, Vol. 67 Issue 1, p35 

    Background Fluticasone furoate (FF) is a novel inhaled corticosteroid with 24 h activity. FF is being developed as a once-daily treatment in combination with the long-acting β2 agonist vilanterol trifenatate for asthma and chronic obstructive pulmonary disease. Objectives To determine the...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sign out of this library

Other Topics